rsv
infect
infant
first
year
life
rapid
develop
vaccin
treatment
therapi
rsv
ad
impetu
need
better
defin
burden
rsv
diseas
global
estim
million
case
rsv
lower
respiratori
tract
infect
year
children
year
age
result
million
admiss
hospit
thousand
death
major
lowand
middleincom
countri
unit
state
estim
children
attend
primari
care
year
rsv
bronchiol
attend
emerg
depart
ed
admiss
hospit
rsv
bronchiol
typic
around
infant
though
previous
healthi
term
infant
admiss
rate
hospit
rsv
bronchiol
low
infant
born
preterm
week
gestat
develop
bronchiol
requir
admiss
hospit
risk
bronchiol
increas
rang
condit
compar
term
infant
includ
preterm
birth
respiratori
rate
rr
cystic
fibrosi
rr
congenit
heart
diseas
rr
chronic
lung
diseas
rr
immunodefici
rr
syndrom
rr
cerebr
palsi
rr
epidemiolog
bronchiol
common
lower
respiratori
tract
infect
children
condit
form
part
spectrum
viral
lower
respiratori
tract
infect
includ
bronchiol
viral
pneumonia
viralinduc
wheez
polar
hemispher
north
south
bronchiol
season
diseas
domin
winter
month
peak
week
around
winter
solstic
tropic
climat
diseas
associ
raini
month
season
dispers
climat
environ
appear
influenc
season
sever
bronchiol
diagnos
clinic
integr
characterist
variabl
sign
symptom
across
broad
age
rang
though
major
case
occur
children
year
age
condit
caus
respiratori
viru
wide
spectrum
diseas
sever
classic
case
would
infant
age
month
age
develop
coryza
subsequ
day
increas
difficulti
breath
consequ
inabl
maintain
adequ
oral
feed
wheez
crackl
heard
auscult
improv
occur
day
though
characterist
harsh
cough
may
persist
day
diagnosi
often
appear
straightforward
wide
rang
diseas
sever
across
skew
broad
age
rang
need
clinic
diagnosi
associ
inconsist
creat
difficulti
establish
precis
data
addit
bronchiol
clinic
diagnosi
appli
infect
agent
major
data
avail
relat
bronchiol
caus
respiratori
syncyti
viru
rsv
infect
within
rsv
bronchiol
focu
high
risk
particular
born
prematur
refer
group
synonym
bronchiol
make
interpret
epidemiolog
data
difficult
may
reduc
understand
bronchiol
caus
nonrsv
lower
risk
patient
particularli
children
born
term
limit
estim
popul
risk
bronchiol
associ
respiratori
viru
infect
approxim
infant
affect
bronchiol
first
year
life
unit
kingdom
use
primari
care
databas
year
incid
children
given
specif
diagnosi
bronchiol
per
children
rise
per
broader
definit
bronchiol
use
captur
potenti
case
studi
highlight
children
typic
lower
respiratori
tract
sign
symptom
clinician
may
ascrib
discret
diagnosi
bronchiol
find
also
found
keyword
bronchiol
viral
lower
respiratori
tract
infect
wheez
respiratori
syncyti
viru
abstract
acut
viral
bronchiol
common
viral
lower
respiratori
tract
infect
young
children
typic
caus
respiratori
syncyti
viru
case
condit
last
day
prolong
cough
mani
children
comorbid
particularli
born
prematur
signific
congenit
heart
diseas
risk
sever
diseas
nasal
obstruct
progress
day
difficulti
feed
increas
work
breath
hypoxemia
crackl
andor
wheez
may
auscult
apnoea
may
present
sign
less
month
age
viral
load
highest
peak
symptom
sever
diseas
approxim
children
admit
hospit
bronchiol
differenti
diagnosi
may
includ
bacteri
pneumonia
congenit
lesion
lung
heart
interstiti
lung
diseas
effect
treatment
admiss
feed
support
nasogastr
intraven
fluid
treatment
hypoxemia
critic
care
support
requir
infant
experienc
respiratori
failur
though
mortal
rate
remain
unchang
practic
within
countri
vari
significantli
align
practic
common
goal
guidelin
vaccin
rsv
advanc
develop
sever
antivir
therapi
rsv
children
acut
symptom
improv
within
day
cough
week
recurr
wheez
common
follow
acut
bronchiol
good
associ
diagnosi
asthma
childhood
infant
born
week
gestat
infant
lower
respiratori
tract
infect
first
year
life
rsv
posit
rsv
neg
infant
rsv
posit
admit
hospit
versu
rsv
neg
recent
studi
suggest
hospit
rate
highrisk
infant
due
rsv
reduc
time
similar
rsv
neg
possibl
result
improv
neonat
care
immunoprophylaxi
highrisk
group
fig
risk
death
much
higher
amongst
highrisk
group
rsv
posit
includ
preterm
congenit
heart
diseas
bronchopulmonari
dysplasia
bronchiol
viral
etiolog
rsv
common
caus
report
case
virus
associ
bronchiol
human
rhinoviru
influenza
coronaviru
human
metapneumoviru
adenoviru
parainfluenza
viru
human
boca
viru
respiratori
viru
rsv
two
strain
b
rsv
associ
sever
diseas
reinfect
season
differ
strain
possibl
sole
infect
agent
rsv
associ
sever
bronchiol
singl
respiratori
viru
infect
coinfect
rsv
rhinoviru
produc
even
sever
diseas
rsv
common
infecti
agent
children
admit
hospit
radiolog
featur
consist
pneumonia
occur
childrenmost
commonli
year
age
young
children
well
immun
rsv
repres
common
caus
lower
respiratori
tract
infect
commenc
upper
respiratori
tract
infect
becom
lower
respiratori
tract
infect
cours
day
infant
particularli
suscept
small
bronchi
like
becom
block
secret
edema
less
welldevelop
abil
respond
clear
viral
infect
histopatholog
natur
limit
sever
case
die
bronchiol
edemat
block
necrot
epithelium
neutrophil
mucu
bind
debri
togeth
airway
obstruct
intensifi
poor
airway
clearanc
associ
loss
cilia
function
occur
within
hour
persist
month
ill
destruct
cilia
consid
caus
viru
replic
mediat
inflamm
rsv
associ
sever
airway
patholog
found
children
die
respiratori
virus
even
mechan
ventil
viral
shed
higher
prolong
younger
infant
sever
diseas
increas
diseas
sever
longer
hospit
stay
use
intens
care
associ
higher
viral
load
rsv
nasopharyng
secret
sever
diseas
associ
infant
risk
factor
includ
lack
adapt
cell
respons
also
rsv
viru
specif
factor
viral
antigen
load
direct
cytotox
effect
determin
rel
contribut
diseas
sever
import
latter
domin
antivir
agent
provid
earli
cours
diseas
may
reduc
sever
wherea
domin
former
might
need
addit
immunomodul
biomark
sought
better
character
risk
greater
diseas
sever
indic
recoveri
infant
hospit
rsv
bronchiol
increas
interleukin
il
secret
polymorph
surfact
protein
associ
increas
risk
intens
care
admiss
cysteinyl
leukotrien
increas
infant
rsv
bronchiol
still
increas
month
follow
infect
sever
diseas
also
associ
increas
serum
cathelicidin
lactat
dehydrogenas
caspas
evid
sever
diseas
may
associ
insuffici
inflammatori
respons
interrelationship
microbiom
bronchiol
also
activ
explor
bronchiol
diagnos
clinic
varianc
clinic
interpret
symptom
physic
find
lead
inconsist
diagnosi
particularli
milder
case
children
year
age
typic
symptom
rhinorrhea
proceed
day
characterist
harsh
moist
cough
pyrexia
typic
although
fever
seen
infant
abil
achiev
adequ
oral
feed
declin
nasal
obstruct
secret
develop
work
breath
increas
time
peak
symptom
day
associ
peak
viral
load
vari
infant
infant
younger
children
particularli
week
age
apnea
may
present
sign
sometim
absenc
featur
bronchiol
apnea
may
temporarili
improv
nasal
suction
like
direct
viral
effect
young
infant
apnea
red
flag
sign
bronchiol
warrant
period
review
supervis
clinic
set
ensur
resolv
patient
like
requir
intens
care
includ
preterm
infant
apnea
low
birth
weight
respiratori
rate
greater
children
tend
relaps
improv
phase
ill
give
confid
clinician
consid
discharg
ed
hospit
physic
find
includ
increas
respiratori
rate
chest
recess
use
accessori
muscl
hyperinfl
wheez
crackl
reduc
arteri
oxygen
satur
physic
find
vari
depend
sleep
state
associ
chang
tidal
volum
respiratori
rate
key
marker
diseas
sever
consid
sever
min
critic
oxygen
satur
may
improv
least
temporarili
remov
nasal
secret
bronchiol
highli
variabl
diseas
requir
assess
diseas
sever
clinician
decis
make
subject
clinic
score
system
develop
attempt
standard
care
minim
varianc
mani
earli
score
deriv
asthma
score
commonli
appli
score
bronchiol
outlin
improv
abil
identifi
risk
deterior
abil
clinic
score
retain
precis
reliabl
score
perform
larger
number
health
care
profession
context
multicent
phase
iii
trial
current
interest
symptom
bronchiol
vari
across
wide
skew
continuum
mildli
increas
work
breath
cough
respiratori
failur
death
often
divid
mild
moder
sever
diseas
perspect
gradat
vari
across
health
care
system
world
health
organ
workshop
provid
candid
definit
differenti
diagnosi
rsv
lower
respiratori
tract
infect
spo
sever
sever
rsv
diseas
spo
inabl
feed
oral
reduc
level
conscious
infant
display
varianc
spo
within
rang
short
period
observ
without
signific
chang
clinic
statu
may
limit
discriminatori
reliabl
definit
secondari
care
perspect
moder
sever
often
consid
need
admiss
hospit
sever
need
critic
care
posit
pressur
support
clinic
score
often
design
identifi
transit
point
level
care
requir
current
avail
evid
concern
transit
point
level
care
poor
treatment
guidanc
particularli
benefit
use
intervent
edward
ie
spo
wardcrit
care
floor
interfac
ie
highflow
nasal
cannula
hfnc
oxygen
continu
posit
airway
pressur
cpap
much
need
guidelin
provid
sign
symptom
alert
clinician
child
risk
deterior
suggest
criteria
admiss
hospit
hospit
like
deterior
extent
provid
critic
care
support
lower
birth
weight
lb
kg
andor
respiratori
rate
day
admiss
chest
radiographi
requir
confirm
diagnosi
bronchiol
chest
radiograph
often
lead
increas
diagnost
uncertainti
featur
may
similar
pneumonia
atelectasi
mucou
plug
loss
volum
consequ
lead
greater
inappropri
use
antibiot
chest
radiographi
reserv
child
atyp
exampl
show
persist
focal
crackl
temperatur
remain
despit
antipyret
respiratori
failur
requir
critic
care
support
laboratori
test
aid
clinic
diagnosi
bronchiol
seriou
bacteri
infect
unusu
complet
blood
count
blood
cultur
unhelp
though
recent
evid
suggest
although
still
uncommon
may
frequent
previous
consid
dehydr
usual
mild
best
assess
clinic
without
electrolyt
measur
approxim
infant
bronchiol
concurr
urinari
tract
infect
urin
cultur
may
valu
persist
febril
infant
particularli
month
age
measur
arterialcapillari
carbon
dioxid
commonli
perform
restrict
children
increas
respiratori
rate
work
breath
despit
oxygen
supplement
clinic
interpret
sign
symptom
difficult
condit
age
boundari
loos
skew
older
age
comorbid
symptom
vari
patient
patient
time
time
natur
lead
variat
diagnosi
differenti
diagnosi
common
understand
clearer
diagnosi
possibl
year
age
guidelin
reflect
howev
constrain
diagnosi
bronchiol
less
year
age
may
reduc
abil
identifi
whole
popul
children
bronchiol
could
benefit
potenti
intervent
gener
broader
bronchiol
often
perform
aid
cohort
patient
within
hospit
increas
recognit
multipl
virus
may
identifi
acut
bronchiol
call
question
benefit
cohort
base
rsv
statu
pcr
diagnost
may
sometim
consid
oversensit
detect
viru
fragment
postinfect
multiplex
pcr
result
interpret
understand
differenti
diagnosi
includ
bacteri
pneumonia
altern
caus
crackl
wheez
increas
work
breath
young
child
persist
crackl
crepit
one
lung
zone
fix
focal
wheez
persist
pyrexia
persist
increas
work
breath
child
appear
otherwis
recov
warrant
evalu
prescient
mind
clinician
bacteri
pneumonia
may
miss
chest
radiograph
similar
appear
poor
discrimin
assum
bacteri
coinfect
risk
low
use
antibiot
bronchiol
associ
faster
recoveri
investig
could
limit
persist
clinic
featur
note
children
sever
diseas
may
role
antibiot
bacteria
isol
lavag
sampl
children
sever
bronchiol
intub
ventil
definit
bronchiol
use
north
america
asia
captur
higher
percentag
older
children
wheez
rhinoviru
domin
infect
agent
children
may
given
diagnosi
viral
induc
wheez
countri
like
continuum
viral
lower
respiratori
tract
infect
across
age
rang
move
current
diagnos
viral
bronchiol
viral
pneumonia
viralinduc
wheezewheezi
bronchiti
clinic
featur
consist
diagnosi
bronchiol
across
differ
guidelin
present
tabl
diagnosi
typic
onset
viral
respiratori
tract
prodrom
proceed
lower
respiratori
symptom
day
south
african
guidelin
consid
hyperinfl
reliabl
clinic
sign
bronchiol
uk
guidelin
provid
proscript
definit
test
nasal
secret
viru
may
help
consolid
clinic
diagnosi
bronchiol
inform
health
care
logist
commonli
use
highest
precis
polymeras
chain
reaction
pcr
diagnost
rang
respiratori
virus
point
care
poc
test
limit
rang
virus
often
rsv
increasingli
precis
cost
effect
test
rsv
common
infect
agent
therapi
addit
supplement
oxygen
hydrat
poorli
support
current
evid
evid
infant
handl
less
get
better
quicker
use
addit
therapi
consid
mind
widespread
variat
across
hospit
countri
manag
treatment
bronchiol
reflect
local
custom
individu
clinician
practic
reduc
variat
associ
health
care
cost
key
aim
bronchiol
manag
present
guidelin
guidelin
care
infant
bronchiol
base
systemat
review
publish
english
avail
unit
kingdom
south
africa
updat
critic
review
therapi
receiv
support
across
guidelin
use
except
supplement
oxygen
chest
physiotherapi
speed
recoveri
antibiot
though
still
wide
use
benefit
bronchiol
addit
bronchodil
less
like
recommend
recent
guidelin
theori
may
greater
benefit
infant
like
develop
asthma
refut
nebul
hyperton
salin
benefit
cystic
fibrosi
earli
trial
bronchiol
larger
welldesign
trial
demonstr
persuas
benefit
recent
year
seen
increas
use
hfnc
oxygen
acut
bronchiol
though
clinic
trial
yet
demonstr
import
clinic
physiolog
benefit
larg
welldesign
trial
progress
begin
report
cpap
benefit
bronchiol
may
prevent
deterior
use
earli
manag
bronchiol
use
hfnc
oxygen
cpap
intub
vari
across
site
irrespect
diseas
sever
better
understand
risk
benefit
intervent
requir
current
effect
pharmacolog
treatment
rsv
ribavirin
previous
use
antivir
treatment
rsv
consid
ineffect
novel
treatment
acut
infect
develop
antivir
nebul
immunoglobulin
rapidli
move
field
seem
probabl
treatment
rsv
becom
avail
next
year
reduct
viral
load
demonstr
adult
challeng
model
rsv
treat
antivir
prevent
spread
rsv
depend
good
hygien
particular
hand
wash
rsv
may
surviv
hour
surfac
contamin
droplet
similar
precaut
appropri
respiratori
viru
infect
associ
bronchiol
mani
hospit
use
poc
test
rsv
determin
cohort
infant
inpati
still
common
practic
call
question
rang
coinfect
respiratori
virus
reveal
pcr
panel
test
children
viral
respiratori
tract
infect
one
viru
detect
prevent
rsv
common
caus
bronchiol
longterm
goal
earli
formalin
inactiv
trial
outcom
antibiot
use
children
bronchiol
receiv
intens
care
though
uncommon
congenit
lesion
may
masquerad
bronchiol
born
mind
children
atyp
clinic
featur
slow
recov
congenit
heart
diseas
may
present
bronchiol
pulmonari
vascular
resist
fall
increas
left
right
shunt
difficult
differenti
children
congenit
less
commonli
acquir
pulmonari
malform
fix
focal
wheez
may
sign
tracheomalacia
bronchomalacia
stenosi
compress
lobar
emphysema
bronchogen
cyst
would
warrant
chest
radiograph
slow
recov
cours
persist
chest
sign
could
infect
congenit
pulmonari
malform
congenit
cystic
adenomatoid
malform
ccam
sequestr
children
persist
fine
crackl
tachypnea
low
often
borderlin
oxygen
satur
may
interstiti
lung
diseas
particularli
neuroendocrin
cell
hyperplasia
nehi
present
recurr
bronchiol
young
children
persist
sometim
focal
crackl
postadenoviru
though
may
also
respiratori
virus
mycoplasma
pneumonia
evalu
postinfecti
bronchiol
obliteran
pibo
see
section
book
manag
bronchiol
support
assist
hydrat
hypoxemia
improv
increas
respiratori
rate
nasal
secret
oral
feed
challeng
sever
diseas
requir
assist
feed
enter
parenter
mean
threshold
support
hydrat
typic
infant
intak
reduc
usual
volum
chosen
percentag
intak
depend
child
statu
expreterm
infant
day
ill
may
support
understand
like
deterior
wherea
robust
term
infant
may
abl
toler
feed
volum
coupl
day
diseas
resolut
nasogastr
feed
easier
administ
intraven
fluid
advantag
recoveri
acut
diseas
oxygen
may
use
treat
hypoxemia
threshold
oxygen
satur
use
supplement
oxygen
vari
across
guidelin
typic
set
sea
level
children
admit
hospit
bronchiol
manag
threshold
spo
safe
clinic
effect
target
threshold
oxygen
satur
admiss
hospit
often
data
suggest
infant
higher
risk
desatur
oxygen
satur
oxygen
desatur
may
howev
disproportion
influenc
decis
admit
children
hospit
much
like
hydrat
statu
previous
mention
context
measur
consid
mani
infant
discharg
home
ed
bronchiol
experi
desatur
event
subsequ
associ
clinic
deterior
hospit
use
intermitt
oxygen
satur
monitor
much
discuss
though
benefit
spo
establish
stabl
spo
oxygen
satur
monitor
stop
use
bronchiol
occur
rsv
posit
rsv
neg
recurr
postinfecti
wheez
reduc
montelukast
inhal
corticosteroid
good
evid
benefit
palivizumab
potenti
azithromycin
though
latter
requir
studi
longer
term
good
evid
children
admiss
hospit
rsv
bronchiol
time
like
diagnosi
asthma
lower
lung
function
age
year
higher
incid
asthma
age
year
question
remain
whether
children
predispos
bronchiol
premorbid
anatomi
consequ
interrelationship
host
viru
specif
effect
develop
asthma
vaccin
associ
sever
enhanc
rsv
diseas
death
possibl
result
inadequ
cell
prime
subsequ
vaccin
develop
cautiou
view
experi
rsv
intraven
immunoglobulin
develop
rapidli
supersed
palivizumab
monoclon
antibodi
deliv
monthli
intramuscular
inject
administ
rsv
season
reduc
hospit
admiss
highrisk
infant
palivizumab
monthli
inject
limit
efficaci
prompt
develop
extend
life
monoclon
antibodi
undergo
licens
trial
preterm
infant
hope
evalu
futur
highrisk
infant
born
term
rsv
vaccin
develop
gain
signific
impetu
last
year
wide
rang
candid
vaccin
develop
pediatr
matern
use
matern
immun
could
provid
passiv
transplacent
protect
infant
first
month
life
http
wwwpathorg
phase
iii
trial
matern
immun
novovax
expect
conclud
children
bronchiol
selflimit
diseas
cough
persist
symptom
resolv
median
day
mani
children
howev
develop
recurr
respiratori
symptom
first
month
follow
ill
consid
part
result
loss
cilia
airway
epitheli
surfac
acut
ill
experi
chronic
symptom
debat
continu
whether
children
sever
bronchiol
recurr
postinfecti
wheez
premorbid
suscept
evid
suggest
poorer
preexist
lung
function
recurr
wheez
year
follow
